Eli Lilly (LLY)
$903.29
5.19 (0.58%)
LLY Stock Quote Delayed 30 Minutes
Indices Get By on ABCs — Wednesday’s IP Market Recap
Apple's earnings momentum turned into big gains Wednesday, Boeing surged and Coca-Cola gained on news of a stock split, all helping markets.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
513,042
Day's Range
$896.90 - $908.52
52-Week Range
$434.34 - $918.50
Dividend & Yield
$4.52 (0.50%)
LLY Stock Predictions, Articles, and Eli Lilly News
10 Pharma Blue Chips to Buy
There are a number of great companies in pharma if you know where to look.
4 Stocks to Watch on Dendreon Earnings
Here's a look at how to trade Dendreon on Monday's earnings report, as well as similar smaller companies that tend to move when DNDN moves.
10 Pharma Stocks to Add to Your Portfolio…Stat
Investors have plenty of reasons to invest in the health care industry. With returns like these, it's no wonder investors are scrambling to own them.
Amylin Gets a Boost From Its Diabetes Drug Approval
FDA approval of Bydureon -- a once-a-week injectable drug -- could make Amylin a takeover target for a Big Pharma.
3 Health Care Plays With Healthy Dividends
These long-term picks fit the bill if you agree this sector's future is sound. Demographic trends alone make for a compelling argument.
The Little Guys Are Pharma’s New Stars
Small and midsize drugmakers are where the action is -- in both research and M&A activity. For healthy dividends, however, Big Pharma still rules.
3 Ways to Turn Analyst Tips Into Huge Profits
While there is nothing wrong with paying attention to what the "smart money" is saying, you do need to know how to interpret it. Here are three simple rules you must know.
Novartis Cutting 2,000 Jobs – So Much for Healthy Healthcare Stocks!
Novartis NYSE:NVS is cutting nearly 2,000 jobs in the United States. The reason? Patent expiration for its blockbuster blood pressure drug Diovan.
3 Stocks Even Wall Street Fat Cats Expect to Crash
When you see all-too-rare sell calls, you better duck and cover. And right now, these three names are on that list.
Wall Street’s 10 Most Hated Stocks
Sears NASDAQ:SHLD, Lexmark NYSE:LXK, Netflix NASDAQ:NFLX and Eli Lilly NYSE:LLY make list of 10 most hated stocks among investment experts.
8 Pharma Stocks in Good Health
The health care sector is a field that will continue to grow as Baby Boomers get old and retire. These eight companies will be at the center of this trend.
WebMD’s Business Model May Need Surgery
Big Pharma’s ad pullback and competition from social media have slammed the health-info site. In fact, the biggest threat to WebMD may be Facebook and Twitter.
7 Feel-Good Pharma Stocks to Buy
Medicine is something few people can afford to go without during times of recession, making these pharma companies good sources of stability.
Why Eli Lilly Could Be a Lottery Stock Pick
If Eli Lilly is successful in delaying the progression of Alzheimer’s disease with its experimental drug, it could make Lipitor look like a mid-sized product. The odds?
Blood-Thinner Drug Race Is Still Wide Open
The major pharmaceutical companies are hoping to supply the definitive treatments, but the medical community hasn't yet declared a winner.
Is It Time to Dump These 4 Health Care ETFs?
These four funds' holdings stand to lose big on health care reform, regardless of the Supreme Court ruling. Investors should assess the damage from the outside.
Bristol-Myers, AstraZeneca Diabetes Drug Gets New Hope
Cleveland Clinic's positive review revitalizes Bristol-Myers, AstraZeneca's dapagliflozin, an experimental drug taking on a growing diabetes management market.
Amylin Stumbles After Lilly Pulls Partnership Plug
As Eli Lilly looks elsewhere for a diabetes drug partner, Amylin Pharmaceuticals stumbles. But Lilly is happy as can be. Here's why.
Shed Dubious Stocks and Funds NOW in an Overbought Market
Europe has bought itself time with their latest bailout package, but it won't last long. Sell overbought stocks and mutual funds before the euphoria wears off.
Lilly Should Survive Patent Loss on Blockbuster Drug Zyprexa
On Oct. 23, Eli Lilly will wave goodbye to the U.S. patent on the best-selling drug in its 135-year history. Here's why investors shouldn't be worried.
